查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1493378

美国肝癌诊断市场规模、份额和趋势分析报告：按测试类型、最终用途、地区和细分市场预测，2024-2030 年

U.S. Liver Cancer Diagnostics Market Size, Share & Trends Analysis Report By Test Type (Laboratory Tests, Imaging, Endoscopy, Biopsy), By End-use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 80 Pages | 商品交期: 2-10个工作天内

价格

美国肝癌诊断市场的成长与趋势：

根据Grand View Research, Inc.的最新报告，美国肝癌诊断市场预计到2030年将达到43.7亿美元，2024年至2030年复合年增长率为4.4%。

这种增长归因于肝癌盛行率的增加、肝癌危险因子盛行率的增加以及技术的进步。该国肝癌的高盛行率凸显了对其预防、检测和治疗的需求。例如，2022年肝癌和肝内胆管癌占所有新发癌症病例的2.2%。

此外，越来越多的政府计划和合作努力透过大量投资、资料主导的方法和国家合作来改变该国的癌症预防、检测、治疗和研究，预计将进一步推动市场成长。例如，由美国癌症研究所 (NCI) 癌症预防部门建立的转化型肝癌 (TLC)联盟专门致力于改善肝癌的监测、早期检测和风险分层，其目的是促进转化型肝癌。

2022 年 2 月启动的癌症登月倡议强调了合作努力在推进癌症研究、治疗和患者照护方面的重要性。 Cancer Moonshot 是一项 2.4 亿美元的投资，旨在支持预防、检测、治疗和生存癌症的新方法。这笔资金将透过卫生高级研究计划局 (ARPA-H) 向从事癌症相关计划的研究人员和创新者提供。这项投资包括开发早期癌症检测工具、在手术过程中可视化癌细胞的创新方法、利用细菌靶向癌细胞等新治疗方法，以及设计治疗设备等更有效的肿瘤检测倡议。

美国肝癌诊断市场报告亮点

  • 从最终用途来看，医院和诊断实验室领域以约 50% 的高份额占据市场主导地位。如此高的比例是由于美国各地医院数量众多。
  • 按测试类型划分，在用于癌症研究和诊断的新型生物标记发现的最新趋势的推动下，分子标记领域预计在预测期内以 9.9% 的最快复合年增长率增长。
  • 临床检测产业由于能够检测生物标记、促进早期检测并提供癌症诊断的预后讯息，因此在 2023 年将占据最大的收入份额，约为 40%。
  • 2023 年 1 月，艾米金 (Amy Kim) 和她在约翰霍普金斯大学医学院的研究团队开发了一种新的肝癌筛检测试，利用尿液分离互补的肿瘤DNA，用于癌症检测。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章美国肝癌诊断市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场推动要素分析
    • 市场限制因素分析
  • 美国肝癌诊断市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章美国肝癌诊断市场：检测类型的估计与趋势分析

  • 2023 年和 2030 年测试类型市场占有率
  • 细分仪表板
  • 按测试类型分類的美国肝癌诊断市场前景
  • 2018-2030年市场规模、预测及趋势分析
  • 试验
  • 影像
  • 内视镜检查
  • 活体组织切片

第五章美国肝癌诊断市场：最终用途估计与趋势分析

  • 2023 年及 2030 年最终用途市场占有率
  • 细分仪表板
  • 按最终用途分類的美国肝癌诊断市场前景
  • 2018-2030年市场规模、预测及趋势分析
  • 医院/诊断实验室
  • 学术/研究机构
  • 製药/CRO实验室

第六章美国肝癌诊断市场：区域估算及趋势分析

  • 2023 年和 2030 年按地区分類的市场占有率份额
  • 美国肝癌诊断市场区域展望
  • 2018-2030年市场规模、预测及趋势分析
  • 西
  • 中西部
  • 东北
  • 西南
  • 东南

第七章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 供应商情况
  • 公司简介
    • Abbott Laboratories
    • Guardant Health
    • Thermo Fisher Scientific, Inc.
    • Illumina, Inc.
    • F.Hoffmann-La Roche Ltd.
    • Qiagen NV
    • Siemens Healthineers
    • Becton, Dickinson &Company
    • Epigenomics AG
    • Koninklijke Philips NV
    • FUJIFILM Healthcare Americas Corporation
Product Code: GVR-4-68040-290-2

U.S. Liver Cancer Diagnostics Market Growth & Trends:

The U.S. liver cancer diagnostics market is anticipated to reach USD 4.37 billion by 2030, exhibiting a CAGR of 4.4% from 2024 to 2030, according to a new report by Grand View Research, Inc. This growth is attributable to the increasing prevalence of liver cancer, rising prevalence of risk factors for liver cancer, and technological advancements. The significant prevalence of liver cancer in the country highlights the need for its prevention, detection, and treatment. For instance, liver and intrahepatic bile duct cancer accounted for 2.2% of all new cancer cases in 2022.

Moreover, the growing number of government programs and collaborative efforts to transform cancer prevention, detection, treatment, and research in the country through substantial investments, data-driven approaches, and nationwide collaborations are further expected to propel market growth. For instance, the Translational Liver Cancer (TLC) Consortium, established by the National Cancer Institute's (NCI) Division of Cancer Prevention, aims to advance translational research specifically focused on improving surveillance, early detection, and risk stratification of liver cancer.

The Cancer Moonshot initiative initiated in February 2022 highlights the importance of collaborative efforts in advancing cancer research, treatment, and patient care. A significant investment of USD 240 million in the Cancer Moonshot supports new ways to prevent, detect, treat, and survive cancer. This funding is likely channeled through the Advanced Research Projects Agency for Health (ARPA-H) to researchers and innovators working on cancer-related projects. The investment includes initiatives such as developing tools for early cancer detection, innovative approaches for visualizing cancer cells during surgery, novel treatment methods like using bacteria to target cancer cells and designing devices for more effective tumor treatment.

U.S. Liver Cancer Diagnostics Market Report Highlights:

  • In terms of end-use, the hospitals and diagnostic laboratories segment dominated the market with the highest share of around 50%. This high share is attributable to the significant presence of hospitals across the country.
  • Based on test type, the molecular markers segment is expected to grow at the fastest CAGR of 9.9% over the forecast period owing to the recent developments in the discovery of novel biomarkers for cancer research and diagnosis.
  • The laboratory tests segment accounted for the largest revenue share of around 40% in 2023 due to their ability to detect biomarkers, facilitate early detection, and provide prognostic information in cancer diagnosis.
  • In Jan 2023, Amy Kim and her team from Johns Hopkins Medicine developed a new screening test for liver cancer, which uses urine to isolate complementary tumor DNA for cancer detection.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Test Type
    • 1.2.2. End-use
    • 1.2.3. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Volume price analysis (Model 2)
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Test type outlook
    • 2.2.2. End-use outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Liver Cancer Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. U.S. Liver Cancer Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's Five Forces
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. U.S. Liver Cancer Diagnostics Market: Test Type Estimates & Trend Analysis

  • 4.1. Test Type Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. U.S. Liver Cancer Diagnostics Market by Test Type Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Laboratory Tests
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.2. Biomarker Tests
      • 4.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.2.2. Oncofetal And Glycoprotein Antigens
      • 4.4.1.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.2.3. Enzymes And Isoenzymes
      • 4.4.1.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.2.4. Growth Factors and Receptors
      • 4.4.1.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.2.5. Molecular Markers
      • 4.4.1.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.2.6. Pathological Biomarkers
      • 4.4.1.2.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.3. Blood Tests
      • 4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Imaging
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Endoscopy
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Biopsy
      • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Liver Cancer Diagnostics Market: End-use Estimates & Trend Analysis

  • 5.1. End-use Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. U.S. Liver Cancer Diagnostics Market by End-use Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Hospitals and Diagnostic Laboratories
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Academic and Research Institutes
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Pharmaceutical and CRO Laboratories
      • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Liver Cancer Diagnostics Market: Region Estimates & Trend Analysis

  • 6.1. Regional Market Share, 2023 & 2030
  • 6.2. U.S. Liver Cancer Diagnostics Market by Region Outlook
  • 6.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
    • 6.3.1. West
      • 6.3.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.2. Midwest
      • 6.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.3. Northeast
      • 6.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.4. Southwest
      • 6.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.5. Southeast
      • 6.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company heat map analysis, 2023
  • 7.4. Company Profiles
    • 7.4.1. Abbott Laboratories
      • 7.4.1.1. Company overview
      • 7.4.1.2. Financial performance
      • 7.4.1.3. Product benchmarking
      • 7.4.1.4. Strategic initiatives
    • 7.4.2. Guardant Health
      • 7.4.2.1. Company overview
      • 7.4.2.2. Financial performance
      • 7.4.2.3. Product benchmarking
      • 7.4.2.4. Strategic initiatives
    • 7.4.3. Thermo Fisher Scientific, Inc.
      • 7.4.3.1. Company overview
      • 7.4.3.2. Financial performance
      • 7.4.3.3. Product benchmarking
      • 7.4.3.4. Strategic initiatives
    • 7.4.4. Illumina, Inc.
      • 7.4.4.1. Company overview
      • 7.4.4.2. Financial performance
      • 7.4.4.3. Product benchmarking
      • 7.4.4.4. Strategic initiatives
    • 7.4.5. F.Hoffmann-La Roche Ltd.
      • 7.4.5.1. Company overview
      • 7.4.5.2. Financial performance
      • 7.4.5.3. Product benchmarking
      • 7.4.5.4. Strategic initiatives
    • 7.4.6. Qiagen N.V.
      • 7.4.6.1. Company overview
      • 7.4.6.2. Financial performance
      • 7.4.6.3. Product benchmarking
      • 7.4.6.4. Strategic initiatives
    • 7.4.7. Siemens Healthineers
      • 7.4.7.1. Company overview
      • 7.4.7.2. Financial performance
      • 7.4.7.3. Product benchmarking
      • 7.4.7.4. Strategic initiatives
    • 7.4.8. Becton, Dickinson & Company
      • 7.4.8.1. Company overview
      • 7.4.8.2. Financial performance
      • 7.4.8.3. Product benchmarking
      • 7.4.8.4. Strategic initiatives
    • 7.4.9. Epigenomics AG
      • 7.4.9.1. Company overview
      • 7.4.9.2. Financial performance
      • 7.4.9.3. Product benchmarking
      • 7.4.9.4. Strategic initiatives
    • 7.4.10. Koninklijke Philips N.V.
      • 7.4.10.1. Company overview
      • 7.4.10.2. Financial performance
      • 7.4.10.3. Product benchmarking
      • 7.4.10.4. Strategic initiatives
    • 7.4.11. FUJIFILM Healthcare Americas Corporation
      • 7.4.11.1. Company overview
      • 7.4.11.2. Financial performance
      • 7.4.11.3. Product benchmarking
      • 7.4.11.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 U.S. liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 3 U.S. liver cancer diagnostics, by end-use, 2018 - 2030 (USD Million)
  • Table 4 U.S. liver cancer diagnostics, by region, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 U.S. liver cancer diagnostics market: market outlook
  • Fig. 9 U.S. liver cancer diagnostics market competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 U.S. liver cancer diagnostics market driver impact
  • Fig. 14 U.S. liver cancer diagnostics market restraint impact
  • Fig. 15 U.S. liver cancer diagnostics: Test type movement analysis
  • Fig. 16 U.S. liver cancer diagnostics: Test type outlook and key takeaways
  • Fig. 17 Laboratory tests market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 18 Biomarker tests market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 19 Oncofetal and glycoprotein antigens market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Enzymes and isoenzymes market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Growth factors and receptors market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Molecular markers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Pathological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Blood tests market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Imaging market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Endoscopy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 U.S. liver cancer diagnostics: End-use movement analysis
  • Fig. 29 U.S. liver cancer diagnostics: End-use outlook and key takeaways
  • Fig. 30 Hospitals and diagnostic laboratories market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Academic and research institutes market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Pharmaceutical and CRO laboratories market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 U.S. liver cancer diagnostics market: Regional movement analysis
  • Fig. 34 U.S. liver cancer diagnostics market: Regional outlook and key takeaways
  • Fig. 35 West market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Midwest market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Northeast market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Southwest market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Southeast market estimates and forecasts, 2018 - 2030 (USD Million)